Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)
Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Royalty Pharma's revenue for the twelve months ending Jun 30, 2026 was $2.54B, up 10.0% year over year. For fiscal 2025 it was $2.38B, up 5.1% from the year before. The highest annual figure on record is $2.38B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38B | +5.1% |
| FY2024 | Dec 31, 2024 | $2.26B | -3.9% |
| FY2023 | Dec 31, 2023 | $2.35B | +5.2% |
| FY2022 | Dec 31, 2022 | $2.24B | -2.3% |
| FY2021 | Dec 31, 2021 | $2.29B | +7.9% |
| FY2020 | Dec 31, 2020 | $2.12B | +17.0% |
| FY2019 | Dec 31, 2019 | $1.81B | +1.1% |
| FY2018 | Dec 31, 2018 | $1.79B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $674.14M | +16.5% |
| Q1 FY2026 | Mar 31, 2026 | $630.58M | +11.0% |
| Q4 FY2025 | Dec 31, 2025 | $621.99M | +4.8% |
| Q3 FY2025 | Sep 30, 2025 | $609.29M | +7.9% |
| Q2 FY2025 | Jun 30, 2025 | $578.67M | +7.7% |
| Q1 FY2025 | Mar 31, 2025 | $568.25M | +0.0% |
| Q4 FY2024 | Dec 31, 2024 | $593.64M | -0.4% |
| Q3 FY2024 | Sep 30, 2024 | $564.69M | +5.3% |
| Q2 FY2024 | Jun 30, 2024 | $537.27M | -0.2% |
| Q1 FY2024 | Mar 31, 2024 | $567.98M | -17.0% |
| Q4 FY2023 | Dec 31, 2023 | $596.07M | +5.4% |
| Q3 FY2023 | Sep 30, 2023 | $536.31M | -6.5% |
| Q2 FY2023 | Jun 30, 2023 | $538.20M | +0.4% |
| Q1 FY2023 | Mar 31, 2023 | $683.97M | +21.7% |
| Q4 FY2022 | Dec 31, 2022 | $565.75M | -1.7% |
| Q3 FY2022 | Sep 30, 2022 | $573.46M | -2.1% |
| Q2 FY2022 | Jun 30, 2022 | $535.96M | -3.4% |
| Q1 FY2022 | Mar 31, 2022 | $562.05M | -1.9% |
| Q4 FY2021 | Dec 31, 2021 | $575.70M | +0.6% |
| Q3 FY2021 | Sep 30, 2021 | $585.77M | +8.8% |
| Q2 FY2021 | Jun 30, 2021 | $554.96M | +8.6% |
| Q1 FY2021 | Mar 31, 2021 | $573.03M | +14.4% |
| Q4 FY2020 | Dec 31, 2020 | $572.14M | +25.1% |
| Q3 FY2020 | Sep 30, 2020 | $538.40M | +16.0% |
| Q2 FY2020 | Jun 30, 2020 | $510.93M | +11.7% |
| Q1 FY2020 | Mar 31, 2020 | $500.88M | – |
| Q4 FY2019 | Dec 31, 2019 | $457.49M | – |
| Q3 FY2019 | Sep 30, 2019 | $464.28M | – |
| Q2 FY2019 | Jun 30, 2019 | $457.61M | – |
See a number that looks wrong?